Pravastatin Sodium Tablets, USP, 10 mg, packaged in a) 90-count bottles (NDC 55111-229-90) and b)...
FDA Drug Recall #D-1038-2017 — Class III — July 11, 2017
Recall Summary
| Recall Number | D-1038-2017 |
| Classification | Class III — Low risk |
| Date Initiated | July 11, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Dr. Reddy's Laboratories, Inc. |
| Location | Princeton, NJ |
| Product Type | Drugs |
| Quantity | 544 bottles |
Product Description
Pravastatin Sodium Tablets, USP, 10 mg, packaged in a) 90-count bottles (NDC 55111-229-90) and b) 500-count bottles (NDC 55111-229-05), Rx only, Manufactured by: Dr. Reddy's Laboratories Limited, Bachupally - 500 090 INDIA; Distributed by: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 USA.
Reason for Recall
Failed Impurities/Degradation Specifications: high out of specification results for related impurity for lot C700220.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot #: a) C700220, Exp 06/18; b) C700220, Exp 06/18
Other Recalls from Dr. Reddy's Laboratories, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0219-2026 | Class III | Varenicline Tablets, 1mg, 56 Tablets, Rx only, ... | Nov 11, 2025 |
| D-0008-2026 | Class II | Succinylcholine Chloride Injection, USP, 200 mg... | Sep 26, 2025 |
| D-0525-2025 | Class II | Omeprazole Delayed-release Capsules, USP, 20mg,... | Jun 30, 2025 |
| D-0365-2025 | Class I | Levetiracetam 0.75% in Sodium Chloride Injectio... | Mar 13, 2025 |
| D-0117-2025 | Class III | Javygtor (sapropterin dihydrochloride) Tablets ... | Nov 22, 2024 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.